Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 May 15;207(10):1269-1270.
doi: 10.1164/rccm.202303-0430ED.

Ascertainment Bias in TB Treatment Trials: Can Systematic Assessment of Objective Endpoints Solve It?

Carole D Mitnick  1 , Andrew J Nunn  2
Affiliations
Editorial

Ascertainment Bias in TB Treatment Trials: Can Systematic Assessment of Objective Endpoints Solve It?

Carole D Mitnick et al. Am J Respir Crit Care Med. .
No abstract available

PubMed Disclaimer

Comment on

  • A Standardized Approach for Collection of Objective Data to Support Outcome Determination for Late-Phase Tuberculosis Clinical Trials.
    Kurbatova EV, Phillips PPJ, Dorman SE, Sizemore EE, Bryant KE, Purfield AE, Ricaldi J, Brown NE, Johnson JL, Wallis CL, Akol JP, Ocheretina O, Van Hung N, Mayanja-Kizza H, Lourens M, Dawson R, Nhung NV, Pierre S, Musodza Y, Shenje J, Badal-Faesen S, Vilbrun SC, Waja Z, Peddareddy L, Scott NA, Yuan Y, Goldberg SV, Swindells S, Chaisson RE, Nahid P. Kurbatova EV, et al. Am J Respir Crit Care Med. 2023 May 15;207(10):1376-1382. doi: 10.1164/rccm.202206-1118OC. Am J Respir Crit Care Med. 2023. PMID: 36790881 Free PMC article. Clinical Trial.

References

    1. Kurbatova EV, Phillips PP, Dorman SE, Sizemore EE, Bryant KE, Purfield AE, et al. AIDS Clinical Trials Group and the Tuberculosis Trials Consortium A standardized approach for collection of objective data to support outcome determination for late-phase TB trials. Am J Respir Crit Care Med . 2023;207:1376–1382. - PMC - PubMed
    1. Dorman SE, Nahid P, Kurbatova EV, Phillips PPJ, Bryant K, Dooley KE, et al. AIDS Clinical Trials Group; Tuberculosis Trials Consortium Four-month rifapentine regimens with or without moxifloxacin for tuberculosis. N Engl J Med . 2021;384:1705–1718. - PMC - PubMed
    1. Nunn AJ, Rusen ID, Van Deun A, Torrea G, Phillips PP, Chiang CY, et al. Evaluation of a standardized treatment regimen of anti-tuberculosis drugs for patients with multi-drug-resistant tuberculosis (STREAM): study protocol for a randomized controlled trial. Trials . 2014;15:353. - PMC - PubMed
    1. Guglielmetti L, Ardizzoni E, Atger M, Baudin E, Berikova E, Bonnet M, et al. Evaluating newly approved drugs for multidrug-resistant tuberculosis (endTB): study protocol for an adaptive, multi-country randomized controlled trial. Trials . 2021;22:651. - PMC - PubMed
    1. Gillespie SH, Crook AM, McHugh TD, Mendel CM, Meredith SK, Murray SR, et al. REMoxTB Consortium Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. N Engl J Med . 2014;371:1577–1587. - PMC - PubMed